Skip to content

Research at St Andrews

The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia: further evidence and meta-analysis

Research output: Contribution to journalArticle

Author(s)

H. Weber, D. Klamer, F. Freudenberg, S. Kittel-Schneider, O. Rivero, C. -J. Scholz, J. Volkert, J. Kopf, J. Heupel, S. Herterich, R. Adolfsson, A. Alttoa, A. Post, H. Grussendorf, A. Kramer, A. Gessner, B. Schmidt, S. Hempel, C. P. Jacob, J. Sanjuan & 5 others M. D. Molto, K. -P. Lesch, C. M. Freitag, L. Kent, A. Reif

School/Research organisations

Abstract

NO is a pleiotropic signaling molecule and has an important role in cognition and emotion. In the brain, NO is produced by neuronal nitric oxide synthase (NOS-I, encoded by NOS1) coupled to the NMDA receptor via PDZ. interactions; this protein-protein interaction is disrupted upon binding of NOS1 adapter protein (encoded by NOS1AP) to NOS-I. As both NOS1 and NOS1AP were associated with schizophrenia, we here investigated these genes in greater detail by genotyping new samples and conducting a meta-analysis of our own and published data. In doing so, we confirmed association of both genes with schizophrenia and found evidence for their interaction in increasing risk towards disease. Our strongest finding was the NOS1 promoter SNP rs41279104, yielding an odds ratio of 1.29 in the meta-analysis. As findings from heterologous cell systems have suggested that the risk allele decreases gene expression, we studied the effect of the variant on NOS1 expression in human post-mortem brain samples and found that the risk allele significantly decreases expression of NOS1 in the prefrontal cortex. Bioinformatic analyses suggest that this might be due the replacement of six transcription factor binding sites by two new binding sites as a consequence of proxy SNPs. Taken together, our data argue that genetic variance in NOS1 resulting in lower prefrontal brain expression of this gene contributes to schizophrenia liability, and that NOS1 interacts with NOS1AP in doing so. The NOS1-NOS1AP PDZ interface may thus well constitute a novel target for small molecules in at least some forms of schizophrenia. 

Close

Details

Original languageEnglish
Pages (from-to)65-85
Number of pages21
JournalEuropean Neuropsychopharmacology
Volume24
Issue number1
Early online date27 Sep 2013
DOIs
Publication statusPublished - Jan 2014

    Research areas

  • Glutamate, Nitric oxide, Association, Schizophrenia, Post-synapse, Prefrontal cortex

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. A case-control genome-wide association study of ADHD discovers a novel association with the tenascin R (TNR) gene

    Hawi, Z., Yates, H., Pinar, A., Johnson, B., Tong, J., Pugsley, K., Dark, C., Pauper, M., Klein, M., Heussler, H. S., Vance, A., Hiscock, H., Fornito, A., Tiego, J., Finlay, A., Franke, B., Gill, M., Kent, L. S. & Bellgrove, M. A., 18 Dec 2018, In : Translational Psychiatry. 8, 8 p., 284.

    Research output: Contribution to journalArticle

  2. Rare DNA variants in the brain derived neurotrophic factor gene increase risk for attention deficit hyperactivity disorder: a next generation sequencing study

    Hawi, Z., Cummins, T. D. R., Tong, J., Arcos-Burgos, M., Zhao, Q., Matthews, N., Newman, D. P., Johnson, B., Vance, A., Heussler, H. S., Levy, F., Easteal, S., Wray, N., Kenny, E., Morris, D., Kent, L., Gill, M. & Bellgrove, M., Apr 2017, In : Molecular Psychiatry. Advance online, p. 580-584 5 p.

    Research output: Contribution to journalArticle

  3. GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorder

    Deckert, J., Weber, H., Villmann, C., Lonsdorf, T. B., Richter, J., Andreatta, M., Arias-Vasquez, A., Hommers, L., Kent, L., Schartner, C., Cichon, S., Wolf, C., Schaefer, N., von Collenberg, C. R., Wachter, B., Blum, R., Schümann, D., Scharfenort, R., Schumacher, J., Forstner, A. J. & 27 othersBaumann, C., Schiele, M. A., Notzon, S., Zwanzger, P., Janzing, J. G. E., Galesloot, T., Kiemeney, L. A., Gajewska, A., Glotzbach-Schoon, E., Mühlberger, A., Alpers, G., Fydrich, T., Fehm, L., Gerlach, A. L., Kircher, T., Lang, T., Ströhle, A., Arolt, V., Wittchen, H-U., Kalisch, R., Büchel, C., Hamm, A., Nöthen, M. M., Romanos, M., Domschke, K., Pauli, P. & Reif, A., 2017, In : Molecular Psychiatry. 22, p. 1431-1439 9 p.

    Research output: Contribution to journalArticle

  4. Pathway analysis in attention deficit hyperactivity disorder: an ensemble approach

    Mooney, M. A., McWeeney, S. K., Faraone, S. V., Hinney, A., Hebebrand, J., IMAGE2 Consortium, German ADHD GWAS Group, Nigg, J. T. & Wilmot, B., Sep 2016, In : American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics . 171, 6, p. 815-826

    Research output: Contribution to journalArticle

  5. Psychiatric gene discoveries shape evidence on ADHD's biology

    Thapar, A., Martin, J., Mick, E., Arias Vásquez, A., Langley, K., Scherer, S. W., Schachar, R., Crosbie, J., Williams, N., Franke, B., Elia, J., Glessner, J., Hakonarson, H., Owen, M. J., Faraone, S. V., O'Donovan, M. C., Holmans, P. & IMAGE 2 Consortium (incl Kent L), 2016, In : Molecular Psychiatry. 21, p. 1202-1207 6 p.

    Research output: Contribution to journalArticle

Related by journal

  1. FUNCTIONAL CHARACTERIZATION OF ATP2C2, A RISK FACTOR FOR LANGUAGE DISORDERS

    Martinelli, A., Diaz, R., Feliciotti, I., Pitt, S. & Paracchini, S., 2019, In : European Neuropsychopharmacology. 29, p. 1194-1195 2 p.

    Research output: Contribution to journalAbstract

  2. IDENTIFICATION OF GENETIC INTERACTIONS INVOLVED IN DYSLEXIA PATHOGENESIS

    Karbalai, N., Czamara, D., Moll, K., Ramus, F., Malik, R., Scerri, T. S., Schumacher, J., Morris, A. P., Bourgeron, T., Monaco, A. P., Paracchini, S., Fisher, S. E., Nothen, M., Schulte-Korne, G. & Muller-Myhsok, B., Oct 2017, In : European Neuropsychopharmacology. 27, p. S183-S184 2 p.

    Research output: Contribution to journalAbstract

  3. Stratified medicine for mental disorders

    Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., Ciccocioppo, R., Cools, R., Escera, C., Fleischhacker, W., Flor, H., Frith, C. D., Heinz, A., Johnsen, E., Kirschbaum, C., Klingberg, T. & 24 othersLesch, K-P., Lewis, S., Maier, W., Mann, K., Martinot, J-L., Meyer-Lindenberg, A., Müller, C. P., Müller, W. E., Nutt, D. J., Persico, A., Perugi, G., Pessiglione, M., Preuss, U. W., Roiser, J. P., Rossini, P. M., Rybakowski, J. K., Sandi, C., Stephan, K. E., Undurraga, J., Vieta, E., van der Wee, N., Wykes, T., Haro, J. M. & Wittchen, H. U., 1 Jan 2014, In : European Neuropsychopharmacology. 24, 1, p. 5-50 46 p.

    Research output: Contribution to journalArticle

ID: 129080182